Share This Link

This statement is incorrect because montelukast for a preschool-age child is specifically prescribed in a chewable tablet form to ensure safe administration and proper absorption. Swallowing a chewable tablet whole can lead to choking hazards in young children and may alter the intended pharmacokinetic profile of the drug. The medication is typically administered once daily in the evening to achieve peak therapeutic levels during the night when asthma symptoms often worsen.

This statement is incorrect because the absorption of montelukast is not significantly affected by the presence of food in the gastrointestinal tract. While it can be taken with or without food, the primary instruction centers on the timing of the dose rather than its association with meals. Instructing a parent that it must be taken with food creates an unnecessary restriction that does not impact the scientific efficacy or the bioavailability of the leukotriene receptor antagonist.

This statement is incorrect because montelukast is categorized as a controller medication rather than a rescue medication. During an acute asthma exacerbation, the pathophysiology involves rapid bronchoconstriction that requires immediate reversal with short-acting beta-agonists like albuterol. Giving montelukast at the start of an attack is ineffective because its mechanism of action involves inhibiting the inflammatory cascade over time, which is too slow to manage the immediate physiological emergency of an acute airway obstruction.

While any controlled breathing technique may provide a minor psychological calming effect, distraction and anxiety reduction are secondary outcomes rather than the primary physiological purpose of pursed-lip breathing. In the context of an asthma attack, the priority is addressing the mechanical ventilation deficit. This choice fails to explain the complex pressure changes within the thoracic cavity that are necessary to counteract the premature collapse of small airways during the expiratory phase of respiration.

This statement is technically inaccurate because the primary goal of pursed-lip breathing is not the speed of carbon dioxide removal, but the completeness of the exhalation. By creating resistance at the lips, the client slows the expiratory flow, which prevents the rapid drop in airway pressure that leads to alveolar air trapping. Speeding up exhalation without this backpressure would actually worsen airway collapse and lead to increased hypercapnia, which is a rise in carbon dioxide.

While an improvement in ventilation can eventually lead to better gas exchange, pursed-lip breathing does not directly or instantly increase serum oxygen levels in the way supplemental oxygen therapy does. Its primary scientific function is mechanical stabilization of the airways. Any rise in oxygen saturation is a tertiary result of improved alveolar ventilation and the reduction of residual volume. Standard pulse oximetry ranges are typically 95.

Collecting a sputum specimen immediately after a meal is contraindicated because it increases the risk of the sample being contaminated with food particles and oral debris. Furthermore, the physical effort required to produce a deep-lung cough shortly after eating can trigger the gag reflex and lead to vomiting or aspiration. Scientifically, the goal is to obtain secretions from the lower respiratory tract, and food contamination interferes with the microscopic visualization and chemical analysis of the sample.

Obtaining a specimen in the evening is not ideal because respiratory secretions tend to settle and become more concentrated overnight during sleep. Scientifically, the highest yield of pathogens and the most representative sample of the lower airway environment are found in the first productive cough of the morning. Evening samples are often thinner and may contain more saliva than actual sputum, which leads to poor diagnostic quality and potentially inaccurate laboratory culture and sensitivity results.

Saving a sputum specimen in a non-sterile container is scientifically unsound because it introduces external bacteria and fungi into the sample. For a culture to be valid, the container must be sterile to ensure that any growth observed in the lab originates solely from the client's lower respiratory tract. Using a contaminated container would lead to false-positive results and the unnecessary prescription of antibiotics. All diagnostic specimens for microbiology must be handled using strict aseptic techniques.

Diarrhea is not a recognized or common adverse effect associated with the use of inhaled albuterol. Albuterol is a sympathomimetic agent that primarily targets beta-2 adrenergic receptors in the lungs to induce bronchodilation. While some systemic absorption can occur, its effects on the gastrointestinal tract do not typically manifest as increased motility or diarrhea. Gastrointestinal side effects are much more common with oral medications or different classes of drugs like certain antibiotics or magnesium-containing antacids.

While some clients might report a headache after using a bronchodilator, it is not the most definitive or physiologically significant adverse effect compared to cardiovascular changes. Headaches associated with albuterol are often secondary to transient changes in blood pressure or systemic vasodilation. However, tachycardia remains the primary concern for nursing monitoring because it directly reflects the drug's impact on the sympathetic nervous system and requires careful assessment of the client's cardiovascular stability during respiratory treatment.

Throat irritation can occur due to the mechanical delivery of the aerosol or the propellants used in the inhaler, but it is not a systemic pharmacological adverse effect of the albuterol molecule itself. While annoying, it does not represent the scientific mechanism of adrenergic stimulation. Rinsing the mouth after use is often recommended to alleviate this local sensation and prevent secondary issues, but it lacks the physiological clinical significance of the systemic beta-adrenergic responses like tremors or increased heart rate.

Using a humidifier might assist with airway moisture or comfort, but it does not address the underlying pathophysiology of obstructive sleep apnea. Sleep apnea in obese clients is primarily caused by the physical collapse of the upper airway due to excess adipose tissue in the neck and pharyngeal area. Humidification does nothing to reduce this mechanical obstruction or the resulting apneic episodes. Therefore, this statement indicates a misunderstanding of the structural nature of the sleep disorder.

Taking a sleeping pill is dangerous for a client with obstructive sleep apnea and indicates a severe lack of understanding. Sedatives and hypnotics further relax the muscles of the upper airway and suppress the central nervous system's drive to wake up when oxygen levels drop or carbon dioxide levels rise. Normal arterial carbon dioxide is 35 to 45 mmHg. Suppressing the arousal response can lead to prolonged periods of hypoxia and potentially fatal respiratory arrest during sleep.

Consuming alcohol before bedtime is contraindicated for clients with sleep apnea. Alcohol acts as a potent central nervous system depressant and a muscle relaxant. Similar to sleeping pills, it causes the muscles of the throat to relax excessively, which worsens the mechanical obstruction of the airway. Alcohol also interferes with the various stages of the sleep cycle and blunts the body's natural protective reflexes that trigger gasping or waking when the airway is blocked.

Tiotropium is not a corticosteroid and does not primarily function to reduce systemic or local airway inflammation. Corticosteroids like fluticasone are used for this purpose by inhibiting the release of inflammatory mediators and decreasing capillary permeability. Tiotropium is a long-acting muscarinic antagonist that focuses on the mechanical relaxation of smooth muscles rather than the underlying inflammatory cascade seen in chronic obstructive pulmonary disease or asthma. Therefore, this statement inaccurately describes its mechanism.

This medication is not a rescue inhaler and should never be used to treat acute bronchospasm or sudden shortness of breath. Short-acting beta-agonists like albuterol are indicated for immediate relief because they work rapidly. Tiotropium has a slow onset of action and is used for maintenance therapy to provide stable bronchodilation over a twenty-four hour period. Using it during an acute attack would be ineffective and potentially dangerous due to the delayed clinical response.

While managing secretions is important in chronic obstructive pulmonary disease, tiotropium does not possess mucolytic properties. It does not thin the viscosity of mucus or increase the effectiveness of the cough reflex. In fact, because it is an anticholinergic, it may actually cause a drying effect on the mucous membranes, leading to xerostomia or thickened secretions in some cases. Mucolytics such as acetylcysteine or guaifenesin are specifically designed to address the issues of thick pulmonary mucus.

Anticholinergic medications inhibit the parasympathetic nervous system, which normally stimulates digestion and salivation. Therefore, a client would experience constipation rather than frequent diarrhea and dry mouth rather than excessive salivation. The blockade of muscarinic receptors reduces the secretions of the exocrine glands and slows down the motility of the gastrointestinal tract. Instructing a client to report diarrhea as a side effect of this specific therapy would be clinically incorrect and physiologically inconsistent.

Blocking the parasympathetic influence on the heart, specifically the vagus nerve, typically leads to an increase in heart rate or tachycardia rather than a slowed heart rate or bradycardia. Additionally, anticholinergics inhibit the sweat glands, leading to decreased sweating and potentially an increased body temperature or flushing. The symptoms described in this choice are more indicative of a cholinergic crisis or parasympathetic overstimulation, which is the exact opposite of what occurs during anticholinergic medication therapy.

Anticholinergic drugs are more likely to cause an increase in heart rate and sometimes an increase in blood pressure depending on the specific agent and dosage. Sleepiness is not a hallmark side effect of inhaled anticholinergics like tiotropium, which mostly acts locally. While some systemic anticholinergics can cause central nervous system effects like confusion or agitation, especially in the elderly, low blood pressure and sleepiness are not the primary adverse effects that a nurse would monitor for.

Using the fluticasone first is incorrect because the inflamed and constricted airways would limit the distribution of the steroid. If the airways are narrow, the medication particles are more likely to deposit in the upper throat and mouth rather than the lower bronchioles. Preparing the lungs requires the rapid relaxation of smooth muscle provided by a bronchodilator. Starting with a steroid inhaler would reduce the overall therapeutic efficacy of the combined treatment regimen.

While it is true that one should wait about one minute between puffs of the same medication to allow for better distribution, the most critical instruction in this specific scenario involves the sequence of two different classes of drugs. The instruction to wait five minutes between puffs of the same medication is helpful but does not address the priority of bronchodilation preceding steroid delivery. Therefore, this is not the most important piece of information for the nurse to include.

Rinsing the mouth is an essential step, but it must be done specifically after using the corticosteroid inhaler, not the albuterol inhaler. Fluticasone can cause local immunosuppression in the oral cavity, leading to the overgrowth of fungus. Rinsing after albuterol is not a standard requirement for preventing complications. The nurse should emphasize rinsing after the steroid to prevent oral candidiasis, making the instruction in this choice both inaccurate and of lower clinical priority.

A pneumothorax involves the presence of air in the pleural space, leading to a collapsed lung. While it can cause respiratory distress and agitation, it usually presents with sudden, sharp chest pain and absent breath sounds on the affected side. Confusion can occur if the pneumothorax leads to severe respiratory failure, but it is not the most direct or common complication of oxygen therapy in a chronic obstructive pulmonary disease patient compared to other metabolic changes.

Hemothorax is the accumulation of blood in the pleural cavity, often resulting from trauma, surgery, or malignancy. It would present with signs of hypovolemia and decreased breath sounds. While it impairs gas exchange, it is an unlikely diagnosis for a patient receiving routine oxygen therapy for chronic obstructive pulmonary disease unless there was a specific acute injury or underlying pathology. It does not directly relate to the physiologic response of oxygen administration in this population.

A pulmonary embolism occurs when a blood clot blocks a pulmonary artery, causing a sudden mismatch in ventilation and perfusion. While this can cause confusion due to a sudden drop in oxygen saturation, it is usually accompanied by acute chest pain, tachycardia, and hemoptysis. While a risk for any chronic patient, confusion in the context of continuous oxygen therapy for chronic obstructive pulmonary disease is more traditionally and frequently associated with the progression of hypoxia or hypercapnia.

While systemic corticosteroids can cause an increase in blood pressure due to sodium and water retention, inhaled fluticasone has minimal systemic absorption when used at recommended doses. It is designed to act locally on the lung tissue to reduce inflammation. Therefore, hypertension is not a typical or expected adverse effect of inhaled fluticasone therapy. Monitoring for blood pressure changes is more relevant for patients taking oral prednisone or other systemic glucocorticoids over a long period.

Polyuria, or excessive urination, is not a side effect of fluticasone. This symptom is more commonly associated with diabetes mellitus or the use of diuretic medications. Corticosteroids do not have a primary mechanism that increases urine output. In fact, systemic steroids might cause some fluid retention, which would lead to decreased rather than increased urine output. There is no scientific link between inhaled fluticasone and the stimulation of the renal system to produce excess urine.

Inhaled corticosteroids like fluticasone are not typically associated with hypoglycemia. On the contrary, if significant systemic absorption were to occur, corticosteroids are known to increase blood glucose levels by stimulating gluconeogenesis and decreasing peripheral glucose uptake. This would result in hyperglycemia rather than hypoglycemia. However, since the inhaled route limits systemic exposure, blood sugar alterations are rare. Hypoglycemia would be an unusual and unexpected finding for a patient using this medication. .